Clinical Trial Update: Regulatory Post Marketing Surveillance Study on Nexavar®

View source ↗

Summary

A completed regulatory post-marketing surveillance study evaluating Nexavar (sorafenib) safety in patients with hepatocellular carcinoma and renal cell carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Hepatocellular, Carcinoma, Renal Cell | Status: COMPLETED